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Fibroblast growth factor-2 (FGF-2), a polypeptide
with regulatory activity on cell growth and differentia-
tion, lacks a conventional secretory signal sequence,
and its mechanism of release from cells remains unclear.
We characterized the role of extracellular vesicle shed-
ding in FGF-2 release. Viable cells released membrane
vesicles in the presence of serum. However, in serum-
free medium vesicle shedding was dramatically down-
regulated, and the cells did not release FGF-2 activity
into their conditioned medium. Addition of serum to
serum-starved cells rapidly induced intracellular FGF-2
clustering under the plasma membrane and into gran-
ules that colocalized with patches of the cell membrane
with typical features of shed vesicle membranes. Shed
vesicles carried three FGF-2 isoforms (18, 22, 24 kDa).
Addition of vesicles to endothelial cells stimulated che-
motaxis and urokinase plasminogen activator produc-
tion, which were blocked by anti-FGF-2 antibodies.
Treatment of intact vesicles with 2.0 M NaCl or hepari-
nase, which release FGF-2 from membrane-bound pro-
teoglycans, did not abolish their stimulatory effect on
endothelial cells, indicating that FGF-2 is carried inside
vesicles. The comparison of the stimulatory effects of
shed vesicles and vesicle-free conditioned medium
showed that vesicles represent a major reservoir of
FGF-2. Thus, FGF-2 can be released from cells through
vesicle shedding.
Fibroblast growth factor-2 (FGF-2)1 is the prototype member
of a family of structurally related heparin binding growth fac-
tors that have mitogenic activity for several cell types and
induce mesenchyme formation (1). FGF-2, a potent inducer of
blood vessel formation (angiogenesis), stimulates smooth mus-
cle and endothelial cell growth, is involved in wound healing,
and plays important roles in the development and differentia-
tion of various organs (2, 3). Elevated levels of FGF-2 have been
implicated in the pathogenesis of several diseases character-
ized by exaggerated neovascularization (4) and in a broad spec-
trum of cancers (5, 6).
FGF-2 exists in five isoforms with molecular masses of 18,
22, 22.5, 24, and 34 kDa (7). The 18-kDa polypeptide is local-
ized primarily in the cytosol (8), whereas forms with higher
molecular mass are found predominantly in the nucleus (7, 9).
All FGF-2 forms entail high affinity interactions with tyrosine
kinase FGF receptors and low-affinity interactions with proteo-
glycans (HSPGs) containing heparan sulfate polysaccharides
(10, 11).
Although FGF-2 is found associated with the extracellular
matrix in vitro and in vivo and exerts its biological activities by
binding to cell membrane receptors, it lacks a conventional
secretory peptide and is not released through the classical
endoplasmic reticulum (ER)-Golgi pathway. It has been pro-
posed that FGF-2 is released from cells through alternative
pathways including cell death, wounding, or sublethal injury
(12, 13). However, FGF-2 release does not parallel the release
of cytoplasmic markers (14). Inhibitors of protein secretion via
the ER-Golgi complex do not block FGF-2 release. In contrast,
reagents or treatments that inhibit exo/endocytosis or energy
production block externalization of FGF-2 in transfected NIH
3T3 or COS-1 cells. A non-classic secretion pathway has there-
fore been proposed for FGF-2 release (15–17). Release of 18-
kDa FGF-2 from transfected COS-1 cells is inhibited by oua-
bain, a known inhibitor of Na,K-ATPase (18), and FGF-2 co-
immunoprecipitates with the  ATPase subunit (19). It has
therefore been proposed that Na,K-ATPase plays an important
role in FGF-2 secretion (16, 20).
Other extracellular proteins devoid of signal sequence in-
clude FGF-1, interleukin 1, interleukin 1, and lectin 14
(L-14). FGF-1 appears to be released in response to stress
conditions as a component of multiprotein aggregates (21, 22),
and a member of the S100 family of Ca2 binding proteins has
been implicated in its release (23, 24). However heat shock does
not affect FGF-2 secretion (15). Secretory pathways via extra-
cellular vesicle production have been proposed for both inter-
leukin 1 and L-14. Externalization of L-14, a signaling mole-
cule highly expressed in muscle cells, is developmentally
regulated. As myogenic cells differentiate, cytosolic L-14 is
concentrated in the cellular ectoplasm beneath regions of the
plasma membrane that appear to evaginate and form extracel-
lular vesicles. It has therefore been suggested that shed mem-
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brane vesicles represent a vehicle for L-14 secretion (25).
IL1 is released from activated immune cells after a second-
ary stimulus such as extracellular ATP acting on P2X (7) re-
ceptors. Mackenzie et al. (26) reported that human THP-1
monocytes shed vesicles from their plasma membranes within
2–5 s after the activation of P2X (7) receptors; 2 min later the
released vesicles contain IL1. The cytokine is then released
in a vesicle-free form at later time points.
Membrane vesicles originate from the plasma membrane
through a mechanism morphologically similar to that of virus
budding. The vesicles are relatively large and heterogeneous in
size; their diameters ranging from 100 to 1000 nm (27, 28).
Vesicle shedding is an active process that requires RNA and
protein synthesis (29) and occurs in viable cells with no signs of
apoptosis or necrosis. Vesicle membranes carry most surface
antigens expressed on the plasma membrane (30); however
they originate from domains of the plasma membrane selec-
tively enriched in membrane components including HLA class
I molecules, 1 integrins, and membrane-bound matrix metal-
loproteinase-9 (31). Vesicle shedding has been implicated in
cell migration and in tumor progression (32), a function that
may be mediated by vesicle membrane-bound proteinases (28,
31, 33–36). Vesicles are also shed by several non-tumor cells
(37, 38) and have been reported to vehicle a variety of regula-
tory factors (25, 26, 29, 30, 36). Vesicles shed by platelets (38)
or monocytes (26) are also enriched in phosphatidyl-serine and
bind annexin V. They were therefore proposed to possess pro-
coagulant activity.
In addition to membrane vesicles, exosomes, a population of
exovesicles released by eukaryotic cells, have also been re-
ported to vehicle secreted proteins. Exosomes are 40–80-nm
extracellular vesicles released by exocytosis of multivesicular
bodies. These structures are part of the endosomal system and
are considered to belong to the category of late endosomes/
lysosomes. Exosomes are probably generated by inward bud-
ding of the vesicle membrane (39, 40) and are enriched in major
histocompatibility complex class I and II molecules, in mem-
bers of the tetraspan protein superfamily (41–43), and in
HSP70 (43, 44). Two cytosolic proteins found in exosomes,
gelactin-3 and annexin II, are also found in the extracellular
environment. Because these proteins do not posses a signal
sequence, it has been suggested that exosomes represent an
unconventional secretion pathway for these proteins (45).
Recently, FGF-2 secretion was analyzed in Chinese hamster
ovary cells expressing FGF-2-GFP fusion protein under control
by the tetracycline resistance transactivator. FGF-2-GFP pro-
tein was shown to translocate to the outer surface of the plasma
membrane; the secreted FGF-2-GFP fusion protein then accu-
mulated in large HSPG-containing protein clusters on the ex-
tracellular surface of the plasma membrane (46). In the present
FIG. 1. Immunolocalization of
FGF-2 in SK-Hep1 cells. Immunolocal-
ization of FGF-2 (a and b) and double
staining of FGF-2/1-integrin (c and d)
and of FGF-2/annexin V (e and f) are
shown. Cells were fixed in serum-free me-
dia (a, c, and e) and 30 min after serum
addition (b, d, and f). Bar  10 m.
Squares show selected areas that were
magnified on the left bottom (2 in a and
b;4 in c, d, e, and f). FGF-2 was detected
using Texas red-conjugated secondary an-
tibodies. 1-Integrin was detected using
FITC-conjugated secondary antibodies.
Biotinylated annexin V added to fixed
cells was detected using FITC-conjugated
streptavidin.
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paper, we tested the hypothesis that these large protein clus-
ters are exovesicles and that vesicle shedding may represent a
mechanism for FGF-2 release from the cell.
EXPERIMENTAL PROCEDURES
Cells and Culture Media—Human SK-Hep1 hepatoma cells were
grown in Dulbecco’s modified Eagle’s medium supplemented with 10%
fetal calf serum (FCS; Euroclone, Celbio). NIH 3T3 cells transfected
with FGF-2 cDNA have been described (15). Transfected and vector-
transfected NIH 3T3 cells were grown in Dulbecco’s minimum essential
medium (Sigma-Aldrich) supplemented with 0.6 g/liter NaHCO3, 500
g/ml geneticin (G418; Invitrogen) and 10% FCS. Bovine GM7373 fetal
aortic endothelial cells (47) were grown in Eagle’s minimal essential
medium (Sigma) supplemented with 10% FCS, vitamins, and essential
and non-essential amino acids. All the cells were negative for myco-
plama contamination by the Hoechst 33258 (Sigma) staining assay.
Immunofluorescence—SK-Hep1 cells seeded at low density (2.000
cells/well) onto microscope coverslips in 12-well culture plates (Nunc)
were grown overnight in complete medium and then in serum-free
medium for 1 week with three medium changes. To study the effect of
serum on the intracellular distribution of FGF-2, medium supple-
mented with 10% FCS was added. After 5, 10, 20, and 30 min of
incubation the cells were fixed in 3.7% formaldehyde for 10 min fol-
lowed by permeabilization with 0.05% Triton X-100 for 5 min. FGF-2
was detected with mouse monoclonal anti-FGF-2 (0.5 mg/ml, 1:200;
Upstate Biotechnology type II) antibody and Texas Red-conjugated
anti-mouse antibodies (1:200; Amersham Biosciences); biotinylated an-
nexin V was added (2 mg/ml) to fixed cells, washed (five times for 5 min
each) with phosphate-buffered saline (PBS), and detected using FITC-
streptavidin (Sigma) (1:500); 1-integrins were detected using FITC-
conjugated C27 mAb (48). In some experiments isolated vesicles were
bound to poly-L-lysine on a coverslip, fixed, permeabilized, and treated
with primary and secondary antibodies as described for cells. Immuno-
stained vesicles were analyzed by confocal microscopy (Olympus 1X70
with Melles Griot laser system).
To detect interactions between vesicle-associated FGF-2 and the cell
membrane, purified vesicles (50 g/ml) were added to sparse GM7373
cell cultures pretreated with cycloheximide (10 g/ml) for 3 h. After 3 h
of incubation the cells were fixed with 3.7% formaldehyde for 10 min,
followed by permeabilization with 0.01% Triton X-100 for 5 min. FGF-2
was detected with mouse anti-FGF-2 monoclonal antibody (0.5 mg/ml,
1:500; Upstate Biotechnology type II) and FITC-conjugated anti-mouse
antibodies (1:500; Amersham Biosciences).
Ultrastructural Analysis—Transmission electron microscopy of ves-
icle shedding was carried out using a standard technique. Briefly, cells
were fixed with 2% glutaraldehyde in culture flasks, scraped, and
post-fixed with 1% OsO4, dehydrated with ethanol, and embedded in
Epon 812. Samples were sectioned, post-stained with uranyl acetate
and lead citrate, and examined with an electron microscope (Philips
CM10, Eindhoven, Netherlands).
For scanning electron microscopy cells were grown on coverslips and
fixed with 2% glutaraldehyde in PBS for 30 min. Critical point dried
samples were glued onto stubs, coated with gold in a SKD040 Balzer
Sputterer, and observed using a Philips 505 scanning electron micro-
scope at 10–30 kV.
Vesicle Purification from Conditioned Medium—Vesicles were puri-
fied from conditioned medium as described (28). Briefly, medium con-
ditioned by subconfluent healthy cells for 3, 6, or 24 h were centrifuged
at 2000  g and at 4000  g for 15 min. The supernatant was ultra-
centrifuged at 105,000  g for 90 min. Pelleted vesicles were resus-
pended in PBS.
In some control experiments, vesicles were purified by affinity bind-
ing of the 4000  g supernatant to biotinylated annexin-V (Pierce) and
bound to Streptavidin MagneSphere Paramagnetic Particles (SA-
PMPs; Promega). To remove components that might bind to the mag-
netic beads in the absence of annexin-V, conditioned medium was
pre-adsorbed with SA-PMPs, in the absence of annexin-V. Vesicles
bound to SA-PMPs were solubilized by incubation with Ca2- and
Mg2-free PBS, 20 mM EDTA for 1 h at room temperature. The amount
of isolated vesicles was determined by measuring protein concentration
by the Bradford microassay method (Bio-Rad) using bovine serum al-
bumin (Sigma) as a standard.
Heparin-Sepharose Adsorption and SDS-PAGE—Purified vesicles
were sonicated three times with 50 pulses for 10 s each and incubated
at 4 °C overnight in an end-over-end mixer with 40–80 l of heparin-
Sepharose (Amersham Biosciences) equilibrated in PBS. After four
washes with PBS, the beads were resuspended in 30 l of reducing
Lae¨mmli buffer and electrophoresed in SDS-3–12.5% gradient poly-
acrylamide gels.
Western Blotting—After electrophoresis in SDS-polyacrylamide gels,
the proteins were blotted onto a nitrocellulose membrane (Hybond;
Amersham Biosciences) that was saturated with 5% horse serum, 0.1%
Tween 20 in PBS for 2 h and then incubated with either monoclonal
anti-FGF-2 (2.5 g/ml; Upstate Biotechnology type II) or anti-HSP70
protein (0.8 g/ml; Sigma H-5147) or anti CD-44 (10 g/ml; Calbiochem
217604) antibodies followed by horseradish peroxidase-conjugated anti-
mouse or anti-rabbit IgG antibodies (1:7500; Sigma) for 1 h at room
temperature. Immunocomplexes were visualized with the ECL Western
blotting kit (Amersham Biosciences) using Hyperfilms.
ERK Phosphorylation—To characterize extracellular signal-regu-
lated kinase-1/2 (ERK1/2) phosphorylation, GM7373 cells were seeded
in 24-well plates (80,000 cells/cm2) in Dulbecco’s modified Eagle’s me-
dium containing 10% FCS. The cells then were starved for 24 h in 0.5%
FCS, followed by treatment with either 50 g/ml SK-Hep1 cell-derived
vesicles or 50 ng/ml human recombinant FGF-2 (49) for the indicated
time. Cell extracts were analyzed by Western blotting with anti-phos-
pho-ERK1/2 antibody (Santa Cruz Biotechnology, Inc.). Immunocom-
plexes were visualized by chemiluminescence with the Supersignal®
West Pico chemiluminescent substrate (Pierce) according to the manu-
facturer’s instructions. To judge uniform loading, the same membrane
was stripped and re-incubated with anti-ERK2 antibody (Santa Cruz
Biotechnology).
Assay for uPA Activity—1.75  106 GM7373 cells (70,000 cells/cm2)
were grown for 28 h in 5 ml of medium supplemented with different
concentrations of vesicles. Cell cultures were washed twice with PBS
and incubated for 18–24 h in serum-free medium. After harvesting the
culture supernatant, the cells were washed twice with PBS and subse-
quently scraped with a rubber policeman. Following centrifugation at
FIG. 2. Time course of vesicle shedding and shed-vesicle sta-
bility in SK-Hep1 cells. a, amount of vesicles recovered from medium
conditioned by 4  107 SK-Hep1 cells. b, amount of vesicles recovered
from medium conditioned by 24 h of 4  107 SK-Hep1 cell growth after
different incubation periods at 37 °C.
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800  g for 10 min at 4 °C, protein concentration was measured by the
Bradford method.
Cell extracts (30 g of proteins) were loaded onto SDS 7.5% poly-
acrylamide gels. Zymography was performed as described (50) with
overlay gels containing 3% non-fat dry milk and 40 g/ml bovine plas-
minogen (Sigma). Densitometric analysis of the lysis bands was per-
formed using Eastman Kodak Co. Science 1D Image Analyzer software.
White bands of caseynolysis of images were converted to dark bands to
better display the activity.
Cell Migration Assay—Falcon cell culture inserts with 8-m pore
polyethylene terephthalate membranes were coated with gelatin (50
g/ml). Five hundred microliters of Dulbecco’s minimum essential me-
dium containing 105 GM7373 cells was added to the upper chamber,
whereas the bottom chamber received 500 l of Dulbecco’s minimum
essential medium with or without the indicated concentrations of ves-
icles, vesicle-free supernatants, and anti-FGF-2 neutralizing antibodies
(type I; Upstate Biotechnology). After 4 h of incubation at 37 °C, the
inserts (16 mm diameter) were removed and fixed in methanol. The
cells on the upper surface of the filter were removed with a cotton swab,
and the cells migrated across the membrane were stained with 1%
crystal violet and counted.
Heparinase and NaCl Treatments—Conditioned media were incu-
bated either with heparinase III 4 milliunits/ml for 2 h at 37 °C or with
FIG. 3. Ultrastructural analysis of
SK-Hep1 cells. Scanning (a–d) and
transmission (e and f) electron micro-
scopic analysis of SK-Hep1 cells grown in
the absence (a, c, and e) or in the presence
of 10% FCS (b, d, and f) is shown.
FIG. 4. Presence of FGF-2 in SK-Hep1 shed membrane vesicles.
A, immunostaining of purified vesicles with biotinylated annexin V and
anti-FGF-2 antibodies. Biotinylated annexin V, added to fixed vesicles,
was detected using FITC-conjugated streptavidin. FGF-2 was detected
using Texas red-conjugated secondary antibodies. Bar  10 m. a and
b, negative controls (a, SK-Hep1 vesicles plus FITC streptavidin; b,
SK-Hep1 vesicles plus Texas red-conjugated secondary antibodies); c,
immunostaining for annexin V; d, immunostaining for FGF-2. B, West-
ern blot analysis of vesicles for FGF-2. Lane 1, human recombinant
FGF-2 (100 ng); lane 2, SK-Hep1 vesicles (recovered from 500 g of
vesicle proteins submitted to heparin-Sepharose chromatography).
FIG. 5. Interaction of vesicle-released FGF-2 with target-cell
plasma membranes and stimulation of ERK1/2 phosphorylation.
A, immunolocalization of released FGF-2. a, untreated cells; b, cells
treated with 50 g/ml Sk-Hep1 vesicles. B, stimulation of ERK1/2
phosphorylation by shed vesicles. Western blot analysis of GM7373
cells extracts by anti-phospho-ERK1/2 antibody (Ph-ERK1/2) and by
ERK2 antibody (ERK2) is shown.  Vesicles, GM7373 cells treated with
50 g/ml SK-Hep1 vesicles for the indicated time;  FGF-2, GM7373
cells treated with 50 ng/ml FGF-2 for the indicated time.
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2 M NaCl (final concentration) for 30 min at 37 °C without or after
sonication (three times with 80 pulses for 30 s each). After centrifuga-
tion at 100,000  g, pelleted vesicles were resuspended in PBS and
assayed for their ability to stimulate uPA expression in GM7373 cells.
RESULTS
FGF-2 Is Associated with Membrane Vesicles Shed from SK-
Hep1 Cells—SK-Hep1 cells produce high levels of FGF-2 (51).
Previous observations (52) have shown that FGF-2 cannot be
detected in serum-free medium conditioned by SK-Hep1 cells,
consistent with the inhibitory effect of serum deprivation on
FGF-2 externalization (15). Similarly, serum deprivation in-
hibits vesicle shedding (28, 53) raising the hypothesis that
FGF-2 externalization and vesicle shedding may represent re-
lated processes. We therefore characterized the effect of serum
on the expression and intracellular localization of FGF-2 in
SK-Hep1 cells. FGF-2 expression was analyzed by Western
blotting of starved cells or cells collected 10 min, 2 h, and 24 h
after serum addition. FGF-2 levels were not affected by serum
FIG. 6. Induction of uPA activity in GM7373 cells by SK-Hep1 vesicles and vesicle-free conditioned medium. GM7373 cells were
incubated for 18 h with different concentration of vesicles. Endothelial cells were lysed and processed for uPA activity as described. a, uPA activity
of GM7373 cells incubated without vesicles (lane 1) or with 25, 50, and 100 g/ml SK-Hep1 vesicles (lanes 2–4). b, effects of differently purified
vesicles. Control, uPA activity of untreated GM7373 cells; Vesicles by centrifugation, uPA activity of cells treated with 6 g/ml SK-Hep1 vesicles
obtained by ultracentrifugation; Vesicles by SAPMPs, uPA activity of cells treated with 6 g/ml SK-Hep1 vesicles obtained by affinity binding to
annexin-V, which had been biotinylated previously and bound to Streptavidin MagneSphere Paramagnetic Particles (SAPMPs; Promega); Residual
pellet, uPA activity of cells treated with 6 g/ml pellet material obtained from conditioned media after vesicles absorption with SAPMPs. c,
comparison between vesicles and vesicle-free media, conditioned by 1 h of Sk-Hep1 cell growth. Control, uPA activity of untreated GM7373 cells;
CM-vesicles, uPA activity of GM7373 cells growing in the presence of vesicle-free conditioned media obtained from 5 ml of SK-Hep1 cultures.
Vesicles, uPA activity of GM7373 cells growing in the presence of vesicles purified from 5 ml of SK-Hep1 conditioned media (3 g/ml). d, comparison
between vesicles and vesicle-free media, conditioned by 3 h of Sk-Hep1 cell growth. Control, uPA activity of untreated GM7373 cells; control  Ab,
uPA activity of GM7373 cells growing in the presence of 2.5 g of inhibitory anti-FGF-2 monoclonal antibodies in 5 ml; CM-vesicles, uPA activity
of GM7373 cells growing in the presence of vesicle-free conditioned media obtained from 5 ml of SK-Hep1 cultures; CM-vesicles  Ab, uPA activity
of GM7373 cells growing in the presence of vesicle-free conditioned media obtained from 5 ml of SK-Hep1 cultures 2.5 g of inhibitory anti-FGF-2
antibodies in 5 ml; Vesicles, uPA activity of GM7373 cells growing in the presence of vesicles purified from 5 ml of SK-Hep1 conditioned media (3
g/ml); Vesicles  Ab, uPA activity of GM7373 cells growing in the presence of vesicle-free conditioned media obtained from 5 ml of SK-Hep1
cultures  2.5 g of inhibitory anti-FGF-2 antibodies in 5 ml. d.u. represents densitometric values of uPA activity, expressed in arbitrary units,
considering 1.0 the basal uPA activity of GM7373 cells.
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(data not shown). Under serum-free conditions, immunofluo-
rescence staining with monoclonal anti-FGF-2 antibody fol-
lowed by confocal microscopy showed that FGF-2 localized in
the nucleus and in the cell cytoplasm, where it formed small
aggregates (Fig. 1a). Addition of serum caused rapid clustering
of FGF-2 in larger patches (Fig. 1b). Under these conditions,
FGF-2 immunoreactive material was found to colocalize with
areas of the cell plasma membranes enriched in 1 integrins
(Fig. 1d) and characterized by an increased capability to bind
annexin V (Fig. 1f), in keeping with a localization of the growth
factor in plasma membrane regions involved in vesicle forma-
tion (26, 38). This colocalization was not observed when cells
were grown under serum-free conditions (Fig. 1, c and e).
In agreement with these and previous observations (28),
SK-Hep1 cells did not release vesicles in the absence of serum.
However, in the presence of FCS SK-Hep1 cells shed a large
amount of vesicles (Fig. 2). Vesicle accumulation in the condi-
tioned medium occurred rapidly, reaching a plateau 3–6 h
after serum addition. Vesicles were produced by viable cell
cultures in which the number of apoptotic or necrotic cells,
evaluated by acridine orange and trypan-blue staining, was
found to be negligible (less than 3%). To analyze vesicle stabil-
ity conditioned media were incubated at 37 °C for different
times before vesicle purification. As shown in Fig. 2b, vesicles
appear to have a short half-life, probably because of their
content in proteolytic enzymes.
Scanning and transmission electron microscopic analysis of
SK-Hep1 cells confirmed that vesicle shedding is induced by
serum addition (Fig. 3). Indeed, serum-starved cells showed a
smooth plasma membrane (a, c, and e), whereas cells grown in
the presence of FCS were characterized by a rough membrane
in the process of shedding membrane vesicles (b, d, and f).
Vesicles appeared to bud from the cell membrane and to en-
close a small amount of cytoplasmic material (f). As shown in
Fig. 3b, vesicle shedding was a generalized phenomenon that
was not limited to isolated, damaged cells. The morphology and
size (300–900 nm diameter) of the vesicles shed by SK-Hep1
cells were similar to those shed by 8701-BC or HT-1080 tumor
cells (28, 34) and clearly distinct from the significantly smaller
exosomes (40).
In another set of experiments, purified vesicles bound to a
poly-L-lysine-coated coverslip were fixed, permeabilized, and
immunostained with anti-FGF-2 antibodies. In parallel, vesi-
cles were assessed for their capacity to bind annexin V. As
shown in Fig. 4a, annexin V-binding vesicles stained inten-
sively with anti-FGF-2 antibodies. Accordingly, Western blot-
ting of isolated vesicles showed FGF-2 immunoreactive bands
of 18, 22, and 24 kDa, consistent with the low and high molec-
ular weight forms of FGF-2 (Fig. 4b). In keeping with previous
observations with different tumor cell types (28, 31, 34, 35),2
SK-Hep1 cell-derived vesicles carried matrix metalloprotein-
ase-2 and matrix metalloproteinase-9 and the hyaluronic acid
receptor, CD-44. In addition, the lack of HSP70 (data not
shown), further distinguished these vesicles from typical exo-
somes (44).
FGF-2 Released from SK-Hep1 Vesicles Binds to the GM7373
Cell Membrane and Generates Intracellular Signaling—To as-
sess the biological significance of vesicle-associated FGF-2, we
tested purified vesicles for their ability to deliver FGF-2 to the
endothelial cell surface and activate downstream signaling.
After incubation of GM7373 endothelial cells with vesicles pu-
rified from SK-Hep1 cell-conditioned medium, the cells, which
do not produce FGF-2, stained positively with antibodies to this
growth factor (Fig. 5A). Downstream signaling triggered by the
binding of FGF-2 to its tyrosine-kinase receptors encompasses
the activation of mitogen-activated protein kinase kinase, with
consequent phosphorylation of ERKs (54). Accordingly, vesicle-
treated GM7373 cells showed a long lasting increase in ERK1/2
phosphorylation (Fig. 5B). Vesicle-mediated ERK1/2 phospho-
2 D. Cassara` and M. L. Vittorelli, unpublished data.
FIG. 7. FGF-2 is released by FGF-2-
transfected NIH-3T3 cells in shed
vesicles. A, time course of vesicle shed-
ding in by FGF-2-transfected NIH-3T3
cells in the absence or in the presence of
10% FCS. B, immunostaining of purified
vesicles with biotinylated annexin V and
anti FGF-2 antibodies. a and b, vesicles
shed by parental NIH 3T3 cells; c and d,
vesicles shed by FGF-2 transfected NIH
3T3 cells; a and c, immunostaining for
annexin V; b and d, immunostaining for
FGF-2. Biotinylated annexin V, added to
fixed vesicles, was detected using FITC-
conjugated streptavidin. FGF-2 was de-
tected using Texas red-conjugated sec-
ondary antibodies. Bar  10 m. C,
Western blot analysis of vesicles for
FGF-2. Lane 1, NIH 3T3 vesicles (50 g);
lane 2, vesicles from FGF-2-transfected
NIH 3T3 cells (50 g).
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rylation appeared to be delayed compared with activation trig-
gered by the recombinant growth factor, probably because of
the slow release of FGF-2 from disrupted vesicles.
Another typical response elicited by FGF-2 is uPA produc-
tion (51, 55). The uPA stimulatory activity of vesicle-associated
FGF-2 was measured by casein/plasminogen zymography of
endothelial cell extracts. As shown in Fig. 6a, vesicles induced
a dose-dependent increase in cell-associated uPA activity. Both
control and vesicle-treated GM7373 cells showed a caseinolytic
band with an apparent molecular mass of 46 kDa, correspond-
ing to bovine uPA and distinct from human uPA (55 kDa). This
observation ruled out the possibility that the increase in uPA
activity was mediated by vesicle-associated human uPA re-
maining bound to the endothelial cell surface.
To confirm that the uPA-inducing activity was associated with
shed vesicles and was not mediated by co-sedimented material in
the vesicle preparation, vesicles were bound to biotinylated an-
nexin V and recovered by affinity chromatography on streptavi-
din-bound magnetic beads. As shown in Fig. 6b, vesicles purified
by this technique had a uPA-inducing activity similar to that of
vesicles isolated by ultracentrifugation.
To compare the stimulatory effects of vesicles and of vesicle-
free supernatants, vesicles, recovered from a fixed volume of
SK-Hep1 conditioned medium, were assessed for their capacity
to induce uPA up-regulation in GM7373 cells. In parallel, the
same volume of vesicle-free supernatant was tested under the
same experimental conditions. As shown by Fig. 6c when this
comparison was made using media collected after 1 h of cell
growth, only vesicles had a clearly detectable stimulatory effect
on GM7373 cells, whereas vesicle-free supernatant was inef-
fective. In media collected after 3 h of cell growth (Fig. 6d) both
vesicles and vesicle-free supernatants had some stimulatory
FIG. 8. Vesicles shed by FGF-2-transfected NIH 3T3 cells induce uPA activity and have chemotactic effects on GM7373 cells. a,
induction of uPA activity in GM7373 cells. GM7373 cells were incubated for 18 h with different concentration of vesicles. Endothelial cells were
lysed and processed for uPA activity as described. uPA activity of GM7373 cells incubated without vesicles (lane 1), with 25 or 50 g/ml
non-transfected NIH 3T3 vesicles (lanes 2 and 3), with 25, 50, or 100 g/ml transfected NIH 3T3 vesicles (lanes 4, 5, and 6) is shown. b, chemiotactic
effects of vesicles shed by FGF-2-producing and non-producing cells. GM7373 endothelial cells were assayed for cell migration in the presence of
indicated concentrations of vesicles shed by non-transfected and FGF-2-transfected NIH 3T3. Vesicles were recovered from media of cells grown
in serum-free (FCS) or in complete medium (FCS). c, inhibition of vesicle-mediated chemotaxis by anti-FGF-2 antibody. GM7373 cells were
incubated with vesicles shed by FGF-2-transfected NIH 3T3 cells (20 g of vesicle protein/ml) with the indicated concentrations of neutralizing
anti-FGF-2 antibody and processed as above. b and c, mean and experimental variability are shown.
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activity, nevertheless vesicles still exerted a stimulatory effect
stronger than the corresponding vesicle-free supernatants. To
confirm that the uPA-inducing activity of SK-Hep1 cell-derived
vesicles was indeed mediated by vesicle-associated FGF-2, ex-
periments were also performed in the presence of neutralizing
anti-FGF-2 antibodies. As shown by Fig. 6d the stimulatory
effects of both vesicles and vesicle-free supernatants were fully
neutralized by anti-FGF-2 monoclonal antibodies (05117; Up-
state Biotechnology). Unrelated monoclonal antibodies belong-
ing to the same isotype (Sigma monoclonal antibody T9026,
against tubulin), tested at the same concentration, did not
modify the stimulatory effects of vesicles and vesicle-free con-
ditioned media (data not shown). These data indicated that
vesicle-associated FGF-2 retains the capacity to up-regulate
uPA expression in endothelial cells and that most, if not all of
the uPA-inducing activity present in the conditioned medium of
SK-Hep1 cells is mediated by FGF-2 initially associated with
vesicles.
FGF-2-transfected NIH 3T3 Cells Release Biologically Active
FGF-2 by Shedding Membrane Vesicles—FGF-2-transfected
NIH 3T3 cells have been shown to release limited but signifi-
cant amounts of this growth factor (15). Therefore, we tested
whether vesicle shedding was also responsible for FGF-2 re-
lease in this cell type. As shown in Fig. 7A, vesicle shedding
was stimulated by serum in both parental and FGF-2-overex-
pressing NIH 3T3 cells. These cells, however, released vesicles
also in serum-free medium. Immunolocalization experiments
and Western blotting analysis showed the presence of low and
high molecular weight FGF-2 isoforms in annexin V-binding
vesicles shed by FGF-2-trasfected cells but not by parental cells
(Fig. 7, B and C).
In keeping with the data obtained with SK-Hep1 cells, ves-
icles purified from the conditioned medium of FGF-2 transfec-
tants showed the capacity to up-regulate uPA expression in
endothelial GM7373 cells (Fig. 8a). In addition, vesicles shed by
FGF-2-producing NIH 3T3 cells induced a chemotactic re-
sponse in endothelial cells, and their effect was abolished by
neutralizing anti-FGF-2 antibody (Fig. 8, b and c). The speci-
ficity of these effects was further demonstrated by the lack of
activity of vesicles released by vector-transfected NIH 3T3
cells.
FGF-2 Is Localized Inside Shed Vesicles—To assess whether
FGF-2 is present inside the vesicles or associated with HSPGs
on their surface, purified vesicles were digested with hepari-
nase III or washed with a high ionic strength solution (2.0 M
NaCl). Both treatments are known to release FGF-2 from
HSPGs (57). The vesicles were then tested for uPA-inducing
activity on GM7373 cells. As shown in Fig. 9, a and b, neither
the heparinase III treatment nor the NaCl wash abolished the
ability of vesicles to up-regulate uPA expression in endothelial
cells. When, however, incubation with NaCl was performed
after sonication, the vesicle stimulatory effect was completely
lost (Fig. 9b). These results are consistent with an intravesicu-
lar localization of the growth factor.
DISCUSSION
FGF-2 is found associated with the extracellular matrix in
vitro and in vivo and interacts with cell membrane receptors.
However, it lacks a hydrophobic signal sequence for secretion
through the ER/Golgi system, and the mechanism(s) of its
release are not understood. Because reagents or treatments
that block protein secretion via the ER-Golgi complex do not
affect FGF-2 release (15) (19), three routes have been proposed
for FGF-2 externalization: cell death (12), sublethal cell injury
(13), or exocytosis via ER/Golgi-independent pathway(s) (15,
19, 46).
In this study we tested the hypothesis that FGF-2 release
from cells occurs by vesicle shedding. Membrane vesicles bud
from the plasma membrane of viable cells and can be purified
from cell-conditioned medium (for a review see Ref. 58). Both
FGF-2 secretion and vesicle shedding are energy-dependent
phenomena (15, 29), and they are not inhibited by reagents
that block protein secretion via the ER-Golgi complex. There-
fore, the two processes appear to be modulated by the same
mechanisms.
The data reported show that serum addition to SK-Hep1
cells that constitutively express high levels of FGF-2 rapidly
results in vesicle shedding and that the intracellular localiza-
tion of FGF-2 is also strongly affected by these culture condi-
tions. Shortly after serum addition to SK-Hep1 cells, FGF-2
appears in granules under the cell membrane and colocalizes
with patches of the cell membranes that show increased con-
FIG. 9. Effects of HSPG removal on the uPA stimulatory effect of vesicles on GM7373 cells. a, effects of heparinase III on uPA
stimulatory effect of vesicles shed by transfected 3T3 cells. Control, uPA activity of untreated GM7373 cells; Untreated vesicles, uPA activity of cells
treated with 20 g/ml of vesicles. Vesicles digested with 4 milliunits/ml of heparinase III, uPA activity of cells treated with 20 g/ml of vesicles
digested with heparinase for 2 h at 37 °C. b, effects of 2 M NaCl incubation on uPA stimulatory effect of vesicles shed by Sk-Hep1 cells. Control,
uPA activity of untreated GM7373 cells; Untreated vesicles, uPA activity of cells treated with 30 g/ml of vesicles. Vesicles incubated with 2 M NaCl,
uPA activity of cells treated with 30 g/ml vesicles incubated for 30 min at 37 °C. Vesicles sonicated and incubated with 2 M NaCl, uPA activity
of cells treated with 30 g/ml vesicles purified from sonicated media and incubated as described.
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centration of 1 integrins and annexin V-binding activity. Ves-
icle membranes were shown to be enriched in 1 integrins (31)
and to have annexin V-binding capacity (26, 38). These obser-
vations indicate that FGF-2 clusters within areas of the cell
membrane where vesicle budding occurs, and FGF-2 is subse-
quently externalized with shed vesicles. Consistent with this
hypothesis, we found that the 18-, 22-, and 24-kDa FGF-2
forms are associated with shed membrane vesicles.
The same FGF-2 isoforms are also present in vesicles shed by
NIH 3T3 cells transfected with FGF-2 cDNA. Based on mor-
phology, size, presence of gelatinolytic enzymes, and annexin
V-binding activity, vesicles shed by SK-Hep1 and by trans-
fected NIH 3T3 cells are similar to membrane vesicles shed by
several tumor (28, 31, 34, 53) or normal cells (25, 26, 38). Their
diameters are much larger than those reported for exosomes
(40). Moreover, exosomes are enriched in HSP70 (43, 44)
whereas vesicles shed by SK-Hep1 or NIH 3T3 cells do not
contain this protein.
Vesicles shed by SK-Hep1 cells or NIH 3T3 cells transfected
with FGF-2 cDNA induce increased uPA expression and migra-
tion (chemotaxis) in vascular endothelial cells, and both these
effects are blocked by neutralizing anti-FGF-2 antibody. Our
data demonstrate that most of the uPA-inducing activity pres-
ent in the conditioned medium of SK-Hep1 cells is associated
with shed vesicles. Because of the short half-life of shed vesi-
cles, the capability of vesicle-associated FGF-2 to interact and
activate FGF receptors and the neutralizing capability of anti-
FGF-2 antibodies are explained by vesicle disruption. The pos-
sibility that FGF-2 released into the culture medium is bound
by vesicle-associated, low affinity HSPG binding sites is ruled
out by our finding that vesicles treated with heparinase or 2.0
M NaCl completely retained their uPA-inducing activity on
endothelial cells, whereas their stimulatory activity was com-
pletely lost when they were sonicated before NaCl treatment.
Direct observations of immunolabeled vesicle-associated
FGF-2 on endothelial cell plasma membranes, and signal
transduction kinetic, indicates that FGF-2, present inside the
vesicles, is delivered to target cells following vesicle break-
down, which occurs spontaneously. Contact of the phospholipid
vesicle membrane with the cell membrane may also result in
increased vesicle permeability and release of the encapsulated
material. This hypothesis is supported by the finding that
liposome-encapsulated FGF-2 retains the ability to up-regulate
endothelial cell expression of uPA (11). The slow release of
FGF-2 induced by contact between vesicle and plasma mem-
branes may represent a mechanism for continuous delivery of
limited amounts of FGF-2 in close vicinity to the cell mem-
brane. The presence of FGF-2 in vesicle-free conditioned media,
which is not observed when media are recovered after very
short conditioning periods, could be also explained by vesicle
disruption; however, at present, we cannot exclude that other
release mechanisms are also involved. In conclusion, vesicle
shedding appears to represent the mechanism, or at least an
important mechanism, for the release of biologically active
FGF-2 from viable cells.
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